Kathryn de Santis
Investor Relations Contact at Sucampo Pharma Americas, Inc.
Profile
Kathryn de Santis is currently the VP-Investor Relations & Corporate Communications at Sucampo Pharma Americas, Inc. She previously held the same position at Sucampo Pharmaceuticals, Inc. and was the Director-Corporate Communications at Human Genome Sciences, Inc. She received an undergraduate degree from Molloy College and an MBA from Pace University.
Kathryn de Santis active positions
| Companies | Position | Start |
|---|---|---|
| Sucampo Pharma Americas, Inc. | Investor Relations Contact | - |
Former positions of Kathryn de Santis
| Companies | Position | End |
|---|---|---|
| SUCAMPO PHARMACEUTICALS, INC. | Investor Relations Contact | 2012-06-28 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Public Communications Contact | - |
Training of Kathryn de Santis
| Pace University | Masters Business Admin |
| Molloy College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
| Sucampo Pharma Americas, Inc. |
- Stock Market
- Insiders
- Kathryn de Santis
